A retrospective Cohort Study Comparing Fracture Rates For Women Receiving Monthly Ibandronate vs Weekly BisphosphonatesPresentation of a Sub-Group Analysis Excluding Patients with Osteopenia, Alendronate 35mg and Corticosteroid UseSummaryNo prospective head-to-head trials comparing the fracture efficacy of the currently marketed weekly and monthly bisphosphonates have been conducted. Due to the large sample size such studies would require to reliably detect differences in fracture risk and the associated high costs, they are considered to be impractical. Whilst providing the highest level of evidence, clinical trials also have inherent limitations. Patients are selected by a number of criteria and therefore usually do not represent the normal patient population. Also due to a protocol, normal clinical practice is usually not reflected. In contrast, database studies allow the assessment of treatments in normal clinical practice. Whilst observational studies have limitations owing to more confounding variables, they do have an important place in evidence-based medicine (especially in the absence of prospective clinical trials), and if well-designed can give some indications regarding the comparative efficacy of osteoporosis therapies in real-world clinical practice. (From the World of Osteoporosis 2008;14: 66-9)Key words: Ibandronate, alendronate, fracture rotes
Article in Turkish(Use the link for full-text in Turkish)
VIBE Çalismasi
VIBE (EValuation of IBandronate Efficacy) [Ibandronatin Etkinliginin Degerlendirilmesi] çalismasi ayda bir defa BONVIVA 150mg (345) ya da haftada bir defa alendronat 35mg/70mg (865) veya risedronat 35mg (972) alan ≥45 yasindaki kadinlarda yapilan retrospektif bir çalismadir. Çalismada ABD’deki arastirma veri tabanlarindaki seçilebilirlik kriterleri, eczane ve medikal ödeme talepleri kullanilmistir. ABD ve Avrupa’da osteoporoz tedavisinde önemli farklar oldugundan, Avrupa’daki bifosfonat prospektüslerini daha iyi yansitan bir popülasyon olusturmak için asagidakiler dislanmistir:• osteopenik hastalar• glukokortikoid kullanan hastalar• alendronat 35mg kullanan hastalarBiz burada 41,858 hasta içeren (876) osteoporotik alt grubun sonuçlarini sunuyoruz.
